Nitazoxanide
From Wikipedia, the free encyclopedia
 |
|
|
Nitazoxanide
|
|
| Systematic (IUPAC) name | |
| [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C12H9N3O5S |
| Mol. mass | 307.283 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 99% |
| Metabolism | Hydrolyzed to tizoxanide |
| Half life | ? |
| Excretion | Renal, biliary and fecal |
| Therapeutic considerations | |
| Pregnancy cat. |
B(US) |
| Legal status | |
| Routes | Oral (tablets and suspension) |
Nitazoxanide, also known by the brand name Alinia, is a synthetic nitrothiazolyl-salicylamide derivative and an anti-protozoal agent. It is approved for treatment of infectious diarrhea caused by Cryptosporidium parvum and Giardia lamblia in patients 1 year of age and older. Following oral administration it is rapidly hydrolyzed to its active metabolite, tizoxanide, which is 99% protein bound. Peak concentrations are observed 1–4 hours after administration. It is excreted in the urine, bile and feces. Untoward effects include abdominal pain, vomiting and diarrhea.
[edit] References
- Mosby's Drug Consult 16th Edition (2006)
- Medline Plus, website : http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/500439.html
- Romark Pharmaceuticals. Alinia® (nitazoxanide) tablets and for oral suspension prescribing information. Tampa, FL: 2005 Jun.
